In June 2026, the Department of Health and Social Care Committee took its final evidence session, completing eight months of oral evidence on food and weight management. What emerged is worth pausing on.

The case for GLP-1 medications has never been stronger but access to medication is not the same as access to the care that makes it work. Ensuring investment translates into lasting returns is one of the biggest tests facing the NHS right now, and we cannot allow this to become a wasted generational opportunity.

Adherence

‍The use of GLP-1 medications alone will not reduce the obesity burden. Real-world adherence to incretin-based therapies for obesity typically lags behind clinical trial data, with typical attrition of 30–40%+ at six months. If treatment pathways remain disconnected, with medication separated from behavioural, nutritional and clinical support, the NHS risks funding the prescription without the care that protects the return.

The challenge is not simply one of access, it is one of pathway design. That means integrating clinical expertise, behavioural support, medication management and long-term outcomes monitoring into a single coordinated model of care. Emerging evidence from integrated care models suggests that adherence rates can be substantially improved when medication is combined with structured behavioural, nutritional and clinical support.

Delivery

‍In our work alongside East Suffolk and North Essex Foundation Trust and SNEE ICB, we support an integrated weight management pathway that reduces waiting times from two years to eight days. These are real-world results delivered through a structured clinical model. Analysis across that cohort demonstrates that we achieve 96 per cent retention at six months, in a medically complex patient group where typical real-world attrition runs at 30 to 40 per cent. Patient outcomes improved and the burden on the system reduced.

Delivering good care can also save money. New evidence has shown that careful, personalised dosing reduced drug spend by nearly 18 per cent compared with standard dosing. If that kind of approach were applied nationally, it is estimated that savings could be in the region of £420 million over six months. Our own experience working alongside East Suffolk and North Essex Foundation Trust and SNEE ICB demonstrates what this can look like in practice.

Prevention

‍What the result also revealed is the limits of what current access patterns allow us to demonstrate. The patients reaching structured pathways today are largely those with the most acute need, the highest clinical complexity, the longest history of failed intervention. This is where commissioning pressure has concentrated. But concentrating resource at the point of greatest acuity means intervening too late.

Opening access to patients earlier, those who are living with obesity but before comorbidities have taken hold, creates the genuine opportunity for prevention rather than rescue.

NICE guidance and the approved indications for GLP-1 therapy sanction intervention at an earlier threshold than the system is currently operating at.

This may prove to be the next major phase in obesity treatment. Today, many patients only gain access once obesity has already driven significant deterioration in health. We are using highly effective medicines as a late-stage intervention when there is growing potential to use them earlier to prevent disease progression. The real opportunity is not simply treating obesity more effectively, but preventing the development of the comorbidities that place the greatest burden on patients and the health service.

If we begin treating patients at this point, two things will follow. We will start to build more robust real-world evidence that obesity-related comorbidities can be prevented in clinically complex, state-funded patient populations. This is the cohort that matters most to the NHS and to policymakers, and where no comparable evidence base yet exists. Private providers treating self-pay patients at lower clinical complexity cannot generate this evidence. And we build the economic case for broader access, demonstrating that earlier intervention costs less and prevents more.

Economic Growth

‍The case for getting this right goes well beyond the clinical. The NHS is already paying for obesity, through downstream complications, comorbidities, emergency care and long-term system burden. The question is not whether to spend, but whether that spend is directed toward treatment that prevents those costs accumulating.

The wider economic implications are equally significant. Obesity is one of the major drivers of economic inactivity, workforce absence and reduced productivity across the UK. As the Government focuses on growth, labour market participation and reducing pressure on public services, the value of effective obesity treatment should not be measured solely through NHS savings. It should also be measured through healthier working lives, greater economic participation and reduced demand across multiple parts of the public sector.

The recent approval of Wegovy for cardiovascular disease is also a hugely significant moment and confirms what many of us have believed for some time. These are whole-body cardiometabolic medicines, not simply weight loss drugs, and the clinical opportunity is expanding faster than the infrastructure to support it.

The Opportunity for Policy Makers

‍The evidence that GLP-1 medications can change outcomes is no longer in dispute. What remains unsolved is whether the NHS will commission the pathways that make those outcomes last.

That means broadening access beyond the most acute cohort to the threshold NICE already sanctions. It means funding wraparound care alongside medication, not as an optional add-on. And it means treating GLP-1 investment the way any serious investor would, by ensuring the infrastructure exists to protect the return. We know what effective pathways look like. The case for building them at scale and building them now is beyond question.

The debate is no longer whether GLP-1 medicines work. The evidence is increasingly clear that they do. The question facing policymakers is whether the NHS truly commits to commissioning obesity treatment as a pathway rather than a prescription. The difference between those two approaches may determine whether this becomes one of the most successful prevention programmes in NHS history, or one of its greatest missed opportunities. The committee report will land in the coming weeks... 

‍